1. Pink Sheet
  2. >>Geography
  3. >>North America

Acquittal Of Former Warner Chilcott Exec May Make Future Prosecutions More Difficult

 
• By Brenda Sandburg

Boston jury clears Carl Reichel of conspiring to pay kickbacks to physicians in case involving dinners and speaker fees.

Government prosecutors may have are harder time going after individuals for health care fraud following a Boston jury's acquittal of Carl Reichel, former president of Warner Chilcott PLC's pharmaceutical division, who was accused of conspiring to pay kickbacks to physicians.

The jury's June 17 not guilty verdict on one count of conspiracy to violate the Anti-Kickback Statute followed a four-week trial. Reichel was indicted in October by the US Attorney's Office for the District of Massachusetts. The government charged that he formulated a sales strategy that provided remuneration to health care professionals in the form of free dinners, speaker payments, and food and drink

More from United States

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 
• By Laura Helbling

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

More from North America